{"id":"libp-rec-vaccine","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Myalgia"}]},"_chembl":{"chemblId":"CHEMBL5090661","moleculeType":"Unknown","molecularWeight":"568.50"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a recombinant vaccine, LIBP-Rec-Vaccine likely contains engineered protein antigens that are presented to the immune system to generate both cellular and humoral immune responses. The vaccine is intended to prime T-cell and B-cell mediated immunity against the target pathogen or disease, potentially providing prophylactic or therapeutic benefit depending on the indication.","oneSentence":"LIBP-Rec-Vaccine is a recombinant protein-based vaccine designed to stimulate immune responses against specific disease targets through antigen presentation.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:18:51.289Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT05599516","phase":"PHASE3","title":"Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) Phase III Clinical Trial","status":"UNKNOWN","sponsor":"National Vaccine and Serum Institute, China","startDate":"2022-11-04","conditions":"COVID-19, Coronavirus Infections","enrollment":16000}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"LIBP-Rec-Vaccine","genericName":"LIBP-Rec-Vaccine","companyName":"National Vaccine and Serum Institute, China","companyId":"national-vaccine-and-serum-institute-china","modality":"Biologic","firstApprovalDate":"","aiSummary":"The LIBP-Rec-Vaccine is a vaccine being studied in a Phase III clinical trial for the prevention of COVID-19 and Coronavirus Infections. The vaccine is being compared to a placebo in a randomized, double-blind, placebo-controlled trial.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":false,"safety":true,"trials":true,"score":3}}